Farmacoriflessioni
Herpes labiale ricorrente: è efficace la profilassi
farmacologica antivirale per via orale?
Recurrent herpes labialis: is the oral pharmacological prophylaxis effective?
Federico Damassa*, Lorenzo Mambelli, Federico Marchetti
UOC di Pediatria e Neonatologia, Ospedale di Ravenna, AUSL della Romagna
*Corso di Formazione Specifica in Medicina Generale
Ottobre 2019 - pagg. 521 -524
Abstract
The prevalence of recurrent herpes labialis ranges between 15% and 40%. In the paediatric population frequent recrudescence leads to different consequences according to the patients’ age. A recent review of clinical studies on the effectiveness of antivirals (acyclovir and valaciclovir) for the prevention of recurrent herpes simplex has considered 4 studies, of which 3 RCT in an adult population and a retrospective study in an adolescent population. The results of the review show that the continuative therapy safely decreases the number of relapses. From a practical point of view a prophylactic antiviral therapy (with acyclovir or, in alternative, with valaciclovir in adolescents) can be proposed for children/adolescents with recurrent herpes labialis and with remarkable clinical (or psychological) involvements. It is not possible to define its duration: if it is effective it may last 6 months, with the possibility to administer it again in case of clinically significant relapses after treatment interruption.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Pittet LF, Curtis N. Does oral antiviral suppressive therapy prevent recurrent herpes labialis in children? Arch Dis Child (Published Online First: 16 July 2019).
2. Ruiz-Villaverde R, Sanchez-Cano D. Chronic suppressive therapy in recurrent herpes labia with valacyclovir in adolescents. Our experience. An Pediatr 2009;71:473-4.
3. Chi CC, Wang SH, Delamere FM, et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev 2015;8:CD010095.
4. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993;118: 268-72.
5. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001;357:1513-8.
6. Panizon F, Marchetti F. Le infezioni da herpesvirus. Medico e Bambino 2006;25:377-82.
7. Looker KJ, Magaret AS, May MT, et al. Global and regional estimates of prevalent and incident Herpes simplex virus type 1 infections in 2012. PLoS One 2015;10: e0140765.
8. Shulman JD. Recurrent herpes labialis in US children and youth. Community Dent Oral Epidemiol 2004;32:402-9.
9. Jensen LA, Hoehns JD, Squires CL. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann Pharmacother 2004;38: 705-9.
10. Griffiths PD. Progress in the clinical management of Herpesvirus infections. Antiviral Chemistry and Chemotherapy 1995;6:191-209.